5 Stocks Targeted By Short Sellers Recently
Altamira Therapeutics Ltd. (NASDAQ:CYTO) is a biotechnology company that is headquartered in Hamilton, Bermuda.
Tenax Therapeutics Inc. (TENX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 339,549 | $1,174,840 | 0.03% | |
| 2. | Vivo Capital Albert Cha And Frank Kung | 208,333 | $720,832 | 0.05% | |
| 3. | Vestal Point Capital Ryan Wilder | 83,333 | $288,332 | 0.02% | |
| 4. | Velan Capital Adam Morgan | 83,333 | $288,332 | 0.26% | |
| 5. | Adage Capital Management Phill Gross And Robert Atchinson | 83,333 | $288,332 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.00 | 1,666 | 1,667 | 2024-08-08 | Filing | ||
| $0.00 | 2,500 | 2,881 | 2024-08-08 | Filing | ||
| $0.00 | 0 | Large Shareholder, Director | 2,019,995 | 2020-09-08 | Filing | |
| $1.46 | 8,543 | Large Shareholder, Director | 2,019,995 | 2020-09-08 | Filing | |
| $0.00 | 0 | Large Shareholder, Director | 2,011,452 | 2020-09-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.39 | 12,950 | 7,149 | 2017-11-14 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,386.9,875 | $52,437 | 0% | |
| 2. | 2,325.575 | $51,088 | 0% | |
| 3. | 1,851.475 | $40,673 | 0% | |
| 4. | 1,779.6,375 | $39,095 | 0% | |
| 5. | 1,188.3,375 | $26,105 | 0% |
News See All
Hedge Funds Are Selling Tenax Therapeutics Inc (TENX)
In this article we will analyze whether Tenax Therapeutics Inc (NASDAQ:TENX) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas...
Is Tenax Therapeutics Inc (TENX) A Good Stock To Buy?
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database.
Hedge Funds Are Warming Up To Tenax Therapeutics Inc (TENX)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Market Movers Today: Cloudera Inc (CLDR), Proteostasis Therapeutics Inc (PTI), Tenax Therapeutics Inc (TENX), Lennar Corporation (LEN), and More
What happened: Shares of Cloudera (NYSE:CLDR) crashed on Wednesday following the cloud software company's fourth-quarter report.
Market Movers Today: Tenax Therapeutics Inc (TENX), Overstock.com Inc (OSTK), Box Inc (BOX), Patterson Companies, Inc. (PDCO), and More
Tenax Therapeutics Inc shares surged 140.5 percent to $ 11.16 as the company reported the publication of preclinical data showing added evidence of levosimendan treatment effects in pulmonary hypertension...
Tenax Therapeutics Inc (TENX) Might Be A Discount Opportunity Ahead Of January Release
Tenax Therapeutics Inc (NASDAQ:TENX) is a North Carolina-based biotechnology company focusing on the development of treatments for what is called the critical care market - a subsection of medical care...
Tenax Therapeutics Inc (TENX): Are Hedge Funds Right About This Stock?
Billionaire hedge fund managers such as Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash...
Here’s What Happened With Alnylam Pharmaceuticals, Inc. (ALNY) and Tenax Therapeutics Inc (TENX)
A couple of companies have had a tough twenty-four hours in the biotech space.
Is Tenax Therapeutics Inc (TENX) Going to Burn These Hedge Funds?
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in the third quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors...